The AI in Business Podcast Building Agile R&D Strategies Through Predictive Analytics - with Scott Bradley of Novartis
10 snips
May 22, 2025 Scott Bradley, VP of AI and Innovation at Novartis, shares insights on how AI is revolutionizing early drug development. He discusses the shift from intuition-based decisions to data-driven strategies in the pharmaceutical industry. The conversation highlights the advancements in protein design and the emergence of niche therapies targeting smaller patient populations. Bradley emphasizes how predictive analytics are reshaping timelines and decision-making, pushing pharma towards a tech-centric model for innovation.
AI Snips
Chapters
Transcript
Episode notes
AI Accelerates Protein Research
- AI dramatically reduces the time to decode protein complexities from months to hours.
- It tackles previously unsolvable problems in drug research and protein synthesis.
Shift From Blockbusters to Niche
- Pharma is shifting from blockbuster drugs to precise, targeted therapies for smaller patient groups.
- AI enables focused drug development but clinical trial capacity limits throughput expansion.
Validate AI Outputs Early
- Validate AI model outputs early in drug development with thorough preclinical testing.
- Build trust by reviewing both successful and failed AI-driven predictions.